Cardiovascular Risk Associated with Methotrexate versus Retinoids in Patients with Psoriasis: A Nationwide Taiwanese Cohort Study

References

• RaychaudhuriSP, FarberEM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15:16–17. doi:10.1046/j.1468-3083.2001.00192.x
   PubMed Web of Science ®Google Scholar
• SalahadeenE, Torp-PedersenC, GislasonG, HansenPR, AhlehoffO. Nationwide population-based study of cause-specific death rates in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1002–1005. doi:10.1111/jdv.1252324909271
   PubMed Web of Science ®Google Scholar
• GelfandJM, NeimannAL, ShinDB, WangX, MargolisDJ, TroxelAB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741. doi:10.1001/jama.296.14.173517032986
   PubMed Web of Science ®Google Scholar
• GelfandJM, DommaschED, ShinDB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129:2411–2418. doi:10.1038/jid.2009.11219458634
   PubMed Web of Science ®Google Scholar
• ArmstrongEJ, HarskampCT, ArmstrongAW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062. doi:10.1161/JAHA.113.00006223557749
   PubMed Web of Science ®Google Scholar
• BoehnckeWH, BoehnckeS, TobinAM, KirbyB. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303–307. doi:10.1111/j.1600-0625.2011.01261.x21410760
   PubMed Web of Science ®Google Scholar
• CharoIF, TaubR. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10:365–376. doi:10.1038/nrd344421532566
   PubMed Web of Science ®Google Scholar
• MenterA, GelfandJM, ConnorC, et al. Joint american academy of dermatology–national psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445–1486.32119894
   PubMed Web of Science ®Google Scholar
• CarreteroG, RiberaM, BelinchonI, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis group of the spanish academy of dermatology and venereology. Actas Dermosifiliogr. 2013;104:598–616. doi:10.1016/j.ad.2013.01.00323891453
   PubMedGoogle Scholar
• CronsteinBN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163–172. doi:10.1124/pr.57.2.315914465
   PubMed Web of Science ®Google Scholar
• ZhangZ, ZhaoP, LiA, et al. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm. 2009;2009:389720. doi:10.1155/2009/38972019884981
   PubMed Web of Science ®Google Scholar
• LackiJK, KlamaK, MackiewiczSH, MackiewiczU, MullerW. Circulating interleukin-10 and interleukin-6 serum levels in rheumatoid-arthritis patients treated with methotrexate or gold salts - preliminary-report. Inflamm Res. 1995;44:24–26. doi:10.1007/BF016304837664026
   PubMed Web of Science ®Google Scholar
• GottliebS, HayesE, GilleaudeauP, CardinaleI, GottliebAB, KruegerJG. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol. 1996;23:404–418. doi:10.1111/j.1600-0560.1996.tb01430.x8915849
   PubMed Web of Science ®Google Scholar
• YuJ, ShaoLE, FrigonNL, LofgrenJ, SchwallR. Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid. Immunology. 1996;88:368–374. doi:10.1046/j.1365-2567.1996.d01-675.x8774352
   PubMed Web of Science ®Google Scholar
• MehtaK, McQueenT, TuckerS, PanditaR, AggarwalBB. Inhibition by all-trans-retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages. J Leukoc Biol. 1994;55:336–342. doi:10.1002/jlb.55.3.3368120450
   PubMed Web of Science ®Google Scholar
• HayashiS, HashimotoS, KitamuraN, HanazawaS, HorieT. Retinoic acid regulates differentially the expression of IL-1 beta and IL-1 receptor antagonist (IL-1ra) in PMA-activated human monocytes. Biochem Biophys Res Commun. 1996;224:574–578. doi:10.1006/bbrc.1996.10668702428
   PubMed Web of Science ®Google Scholar
• NaSY, KangBY, ChungSW, et al. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB. J Biol Chem. 1999;274:7674–7680. doi:10.1074/jbc.274.12.767410075655
   PubMed Web of Science ®Google Scholar
• ChadwickCC, ShawLJ, WinnekerRC. TNF-alpha and 9-cis-retinoic acid synergistically induce ICAM-1 expression: evidence for interaction of retinoid receptors with NF-kappa B. Exp Cell Res. 1998;239:423–429. doi:10.1006/excr.1997.39139521860
   PubMed Web of Science ®Google Scholar
• De BreeA, VerschurenWM, KromhoutD, KluijtmansLA, BlomHJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002;54:599–618. doi:10.1124/pr.54.4.59912429870
   PubMed Web of Science ®Google Scholar
• van EdeAE, LaanRF, BlomHJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41:658–665. doi:10.1093/rheumatology/41.6.65812048292
   PubMed Web of Science ®Google Scholar
• RoubilleC, RicherV, StarninoT, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480–489. doi:10.1136/annrheumdis-2014-20662425561362
   PubMed Web of Science ®Google Scholar
• AhlehoffO, SkovL, GislasonG, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29:1128–1134. doi:10.1111/jdv.1276825303139
   PubMed Web of Science ®Google Scholar
• ChenYJ, ChangYT, ShenJL, et al. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum. 2012;64:1879–1887. doi:10.1002/art.3433522161801
   PubMed Web of Science ®Google Scholar
• LanCC, KoYC, YuHS, et al. Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. Acta Derm Venereol. 2012;92:349–352. doi:10.2340/00015555-128322294195
   PubMed Web of Science ®Google Scholar
• ProdanovichS, MaF, TaylorJR, PezonC, FasihiT, KirsnerRS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52:262–267. doi:10.1016/j.jaad.2004.06.01715692471
   PubMed Web of Science ®Google Scholar
• AhlehoffO, SkovL, GislasonG, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197–204. doi:10.1111/j.1365-2796.2012.02593.x22963528
   PubMed Web of Science ®Google Scholar
• RidkerPM, EverettBM, PradhanA, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752–762. doi:10.1056/NEJMoa180979830415610
   PubMed Web of Science ®Google Scholar
• ChangYT, ChenTJ, LiuPC, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009;89:262–266. doi:10.2340/00015555-064219479122
   PubMed Web of Science ®Google Scholar
• HsiehC-Y, Su-C-C, ShaoS-C, et al. Taiwan’s national health insurance research database: past and future. Clin Epidemiol. 2019;11:349–358. doi:10.2147/CLEP.S19629331118821
   PubMed Web of Science ®Google Scholar
• LeeMS, YehYC, ChangYT, LaiMS. All-cause and cause-specific mortality in patients with psoriasis in taiwan: a nationwide population-based study. J Invest Dermatol. 2017;137:1468–1473.28257796
   PubMed Web of Science ®Google Scholar
• HsiehCY, ChenCH, LiCY, LaiML. Validating the diagnosis of acute ischemic stroke in a national health insurance claims database. J Formos Med Assoc. 2015;114:254–259. doi:10.1016/j.jfma.2013.09.00924140108
   PubMed Web of Science ®Google Scholar
• ChengCL, LeeCH, ChenPS, LiYH, LinSJ, YangYH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol. 2014;24:500–507. doi:10.2188/jea.JE2014007625174915
   PubMed Web of Science ®Google Scholar
• QuanH, SundararajanV, HalfonP, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139. doi:10.1097/01.mlr.0000182534.19832.8316224307
   PubMed Web of Science ®Google Scholar
• BenedettoU, HeadSJ, AngeliniGD, BlackstoneEH. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg. 2018;53:1112–1117. doi:10.1093/ejcts/ezy16729684154
   PubMed Web of Science ®Google Scholar
• AustinPC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. doi:10.1080/00273171.2011.56878621818162
   PubMed Web of Science ®Google Scholar
• SeegerJD, WilliamsPL, WalkerAM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14:465–476. doi:10.1002/pds.106215651087
   PubMed Web of Science ®Google Scholar
• ColeSR, HernanMA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75:45–49. doi:10.1016/j.cmpb.2003.10.00415158046
   PubMed Web of Science ®Google Scholar
• HernanMA, RobinsJM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60:578–586. doi:10.1136/jech.2004.02949616790829
   PubMed Web of Science ®Google Scholar
• AustinPC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–3107.19757444
   PubMed Web of Science ®Google Scholar
• LeeWC. Bounding the bias of unmeasured factors with confounding and effect-modifying potentials. Stat Med. 2011;30:1007–1017. doi:10.1002/sim.415121472760
   PubMed Web of Science ®Google Scholar
• SchneeweissS. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15:291–303. doi:10.1002/pds.120016447304
   PubMed Web of Science ®Google Scholar
• KalbRE, StroberB, WeinsteinG, LebwohlM. Methotrexate and psoriasis: 2009 national psoriasis foundation consensus conference. J Am Acad Dermatol. 2009;60:824–837. doi:10.1016/j.jaad.2008.11.90619389524
   PubMed Web of Science ®Google Scholar
• AhlehoffO, GislasonGH, CharlotM, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147–157.21114692
   PubMed Web of Science ®Google Scholar
• ChoiHK, HernanMA, SeegerJD, RobinsJM, WolfeF. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–1177. doi:10.1016/S0140-6736(02)08213-211955534
   PubMed Web of Science ®Google Scholar
• SolomonDH, AvornJ, KatzJN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3790–3798. doi:10.1002/art.2225517136752
   PubMed Web of Science ®Google Scholar
• BackM, HanssonGK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015;12:199–211. doi:10.1038/nrcardio.2015.525666404
   PubMed Web of Science ®Google Scholar
• WhittleSL, HughesRA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43:267–271. doi:10.1093/rheumatology/keh08814963199
   PubMed Web of Science ®Google Scholar
• SternRS, FitzgeraldE, EllisCN, LoweN, GoldfarbMT, BaughmanRD. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol. 1995;33:44–52. doi:10.1016/0190-9622(95)90008-X7601945
   PubMed Web of Science ®Google Scholar
• LernerDJ, KannelWB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383–390. doi:10.1016/0002-8703(86)90155-93946178
   PubMed Web of Science ®Google Scholar
• ElvebackLR, ConnollyDC, MeltonLJ3rd. Coronary heart disease in residents of Rochester, Minnesota. VII. Incidence, 1950 through 1982. Mayo Clin Proc. 1986;61:896–900. doi:10.1016/S0025-6196(12)62612-33762228
   PubMed Web of Science ®Google Scholar
• MenterA, KormanNJ, ElmetsCA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–485. doi:10.1016/j.jaad.2009.03.02719493586
   PubMed Web of Science ®Google Scholar
• AtzeniF, Rodríguez-CarrioJ, PopaCD, NurmohamedMT, SzűcsG, SzekaneczZ. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:270–290.33833437
   PubMed Web of Science ®Google Scholar
• SchneeweissS. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858–868. doi:10.1002/pds.192620681003
   PubMed Web of Science ®Google Scholar
• PocockSJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials. 1997;18:530–545; discussion 546–539. doi:10.1016/S0197-2456(97)00008-1
   Google Scholar
• RothmanKJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46. doi:10.1097/00001648-199001000-000102081237
   PubMedGoogle Scholar
• FeiseRJ. Do multiple outcome measures require p-value adjustment?BMC Med Res Methodol. 2002;2:8. doi:10.1186/1471-2288-2-812069695
   PubMedGoogle Scholar